Pembrolizumab +/- SD-101 in Hormone-Naïve Oligometastatic Prostate Cancer With RT and iADT
Status:
Recruiting
Trial end date:
2023-10-31
Target enrollment:
Participant gender:
Summary
This is a non-comparative open-label multicenter Phase 2 clinical trial combining
stereotactic body radiation therapy (SBRT) and pembrolizumab with or without intratumoral
SD-101 in patients with newly diagnosed hormone-naive oligometastatic prostate cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Lawrence Fong
Collaborators:
Dynavax Technologies Corporation Merck Sharp & Dohme Corp. Prostate Cancer Foundation